Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34(+) CD38(low) blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial. High peripheral blood CD34(+) CD38(low) blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0.0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.

Original publication




Journal article


Br J Haematol

Publication Date





80 - 84


acute myeloid leukaemia, flow cytometry, older patients, prognostic, ADP-ribosyl Cyclase 1, Aged, Aged, 80 and over, Antigens, CD34, Flow Cytometry, Humans, Immunophenotyping, Induction Chemotherapy, Leukemia, Myeloid, Acute, Middle Aged, Prognosis, Survival Analysis